PLSCR4 Antibody

What is PLSCR4 and what characterization methods are most effective?

PLSCR4 (Phospholipid Scramblase 4) is a member of the PLSCR family that mediates the bidirectional, non-specific, and headgroup-independent transbilayer movement of phospholipids (PS) across lipid bilayers, particularly in Ca²⁺-dependent processes. The most effective characterization methods include:

• Western blotting with specific PLSCR4 antibodies targeting various domains (AA 122-151, AA 1-303, AA 225-274)

• Immunohistochemistry on paraffin-embedded sections

• Co-immunoprecipitation to study interactions with binding partners such as GSDMD and CD4

When characterizing PLSCR4, it's essential to consider its subcellular localization, which is predominantly at the plasma membrane in many cell types, including CD4-positive T lymphocytes . Expression analysis should include appropriate controls to distinguish PLSCR4 from other scramblase family members, as they share structural similarities.

What are the optimal experimental conditions for using PLSCR4 antibodies in different applications?

For optimal results with PLSCR4 antibodies across different applications, consider the following conditions:

Western Blotting (WB):

• Recommended dilution: 1:500-1:1000

• Sample preparation: Complete cell lysis with phosphatase inhibitors

• Detection method: Enhanced chemiluminescence systems

• Blocking solution: 5% non-fat milk in TBST

Immunohistochemistry (IHC):

• Antigen retrieval: Heat-induced epitope retrieval in citrate buffer (pH 6.0)

• Antibody incubation: Overnight at 4°C

• Signal amplification: Avidin-biotin complex method recommended

• Counterstaining: Hematoxylin for nuclei visualization

Immunoprecipitation (IP):

• Lysis buffer: RIPA buffer with protease inhibitors

• Antibody amount: 2-5 μg per 500 μg of total protein

• Incubation time: 4 hours to overnight at 4°C

• Wash stringency: Multiple washes with decreasing salt concentration

These conditions should be optimized based on the specific antibody used, as different epitope-targeting antibodies may require modified protocols .

How does antibody selection affect detection of different PLSCR4 domains?

The selection of PLSCR4 antibodies targeting different domains significantly impacts experimental outcomes:

In ARDS research specifically, antibodies recognizing the central domain have proven valuable for tracking PLSCR4's involvement in pyroptosis and interactions with GSDMD .

What methodological approaches can resolve contradictory findings when using different PLSCR4 antibodies?

When facing contradictory results with different PLSCR4 antibodies, implement the following systematic troubleshooting approach:

• Epitope mapping validation:

  • Perform peptide competition assays with synthetic peptides corresponding to the epitope

  • Use recombinant PLSCR4 fragments as positive controls

  • Validate antibody specificity across multiple techniques (WB, IHC, IP)

• Cross-reactivity assessment:

  • Test antibodies on PLSCR4 knockout/knockdown models

  • Evaluate potential cross-reactivity with other PLSCR family members, especially PLSCR1

  • Perform immunoprecipitation followed by mass spectrometry to identify all bound proteins

• Technical validation:

  • Compare fixation protocols (PFA vs. methanol) for differential epitope exposure

  • Adjust antigen retrieval conditions (pH, temperature, duration)

  • Standardize detection systems and control for batch variation

• Complementary approaches:

  • Supplement antibody-based detection with mRNA expression analysis

  • Use tagged recombinant PLSCR4 as an internal control

  • Apply proximity ligation assays to confirm specific interactions

When studying PLSCR4's role in pyroptosis, contradictory findings may arise from differential recognition of PS-bound versus unbound conformations of PLSCR4. Using multiple antibodies targeting different domains in parallel can help provide comprehensive data on protein state and localization .

How can researchers effectively use PLSCR4 antibodies to study its interaction with GSDMD in pyroptosis?

To investigate PLSCR4-GSDMD interactions in pyroptosis, the following methodological approach is recommended:

• Co-immunoprecipitation optimization:

  • Use membrane-compatible lysis buffers (containing 0.5-1% NP-40 or digitonin)

  • Cross-link proteins prior to lysis to preserve transient interactions

  • Perform reciprocal IPs with both anti-PLSCR4 and anti-GSDMD antibodies

  • Include phosphatase inhibitors to preserve phosphorylation-dependent interactions

• Subcellular fractionation:

  • Separate membrane fractions to enrich for PLSCR4-GSDMD complexes

  • Use differential centrifugation followed by immunoblotting

  • Compare distribution before and after pyroptotic stimuli (e.g., LPS treatment)

• Proximity-based assays:

  • Implement FRET or BRET assays with tagged proteins

  • Use proximity ligation assays on fixed cells to visualize endogenous interactions

  • Correlate interaction dynamics with pyroptotic events using live-cell imaging

• Functional validation:

  • Use siRNA knockdown of PLSCR4 to assess effects on GSDMD-NT localization

  • Measure PS externalization and GSDMD pore formation in parallel

  • Quantify IL-1β and IL-18 release as functional readouts of pyroptosis

Research by Lu et al. demonstrated that PLSCR4 alleviates pyroptosis by transporting PS to the outside of the cell membrane, which blocks the formation of pyroptosis pores composed of GSDMD. This suggests that PLSCR4 may serve as a regulatory mechanism in pyroptosis through its interaction with GSDMD-NT .

What are the key technical considerations for using PLSCR4 antibodies in ARDS research models?

When applying PLSCR4 antibodies in ARDS research models, several technical considerations are critical:

• Model-specific validation:

  • Validate antibody reactivity in both murine and human samples

  • Ensure consistent epitope recognition across species if using cross-reactive antibodies

  • Test antibody performance in both in vitro and in vivo ARDS models

• Sample preparation optimization:

  • For lung tissue: Use specialized fixatives to preserve alveolar architecture

  • For HPMECs: Optimize gentle detachment methods to preserve membrane proteins

  • Include mechanical ventilation controls in animal models to account for ventilator-induced effects

• Timing considerations:

  • Design time-course experiments to capture dynamic changes in PLSCR4 expression

  • Correlate PLSCR4 levels with disease progression markers

  • Compare acute vs. resolution phases of ARDS

• Complementary measurements:

  • Simultaneously assess barrier function (tracer flux assays)

  • Measure inflammatory cytokines (IL-1β, IL-18) as functional readouts

  • Quantify PS externalization as a marker of PLSCR4 activity

When designing siRNA knockdown experiments for PLSCR4 in ARDS models, the delivery method is crucial. In mouse models, administration through fundus venous plexus injection has proven effective, with recommended dosing of 150 μL PLSCR4 siRNA (40 μM) combined with 16 μL Lipofectamine 2000 diluted in 100 μL DEPC-treated water .

How can researchers distinguish between PLSCR4 and other PLSCR family members in experimental settings?

Discriminating between PLSCR family members requires careful experimental design:

• Antibody selection strategy:

  • Target divergent epitopes unique to PLSCR4

  • Use type-II divergence analysis tools like DIVERGE 3.0 to identify regions with evolutionary divergence

  • Validate antibody specificity against recombinant PLSCR1-4 proteins

• Expression pattern analysis:

  • Perform multi-color immunofluorescence to co-localize PLSCR family members

  • Use tissue-specific expression patterns as an additional discriminating factor

  • Quantify relative expression levels of different PLSCR proteins

• Functional discrimination:

  • Design assays targeting unique functions (e.g., PLSCR4's role in pyroptosis)

  • Assess differential binding partners through comparative IP-MS

  • Investigate calcium-dependent PS scrambling efficiency differences

• Genetic approaches:

  • Design isoform-specific siRNAs targeting unique 3'UTR regions

  • Use CRISPR-Cas9 with guides targeting PLSCR4-specific sequences

  • Perform rescue experiments with PLSCR4 constructs resistant to siRNA

The localization patterns can also help distinguish PLSCR family members. While PLSCR1, PLSCR3, and PLSCR4 are all transmembrane proteins with predominant plasma membrane localization in T cells, PLSCR4 shows distinct interaction patterns with CD4 receptors, which can be used as a discriminating feature in immunological studies .

What are the technical considerations when using PLSCR4 antibodies to study its interaction with CD4 receptors?

For investigating PLSCR4-CD4 interactions, the following technical approach is recommended:

• Co-localization assessment:

  • Use high-resolution confocal or super-resolution microscopy

  • Implement three-color immunofluorescence (PLSCR4, CD4, and membrane marker)

  • Quantify co-localization using Pearson's or Mander's coefficients

• Interaction domain mapping:

  • Use deletion mutants of PLSCR4 (especially targeting the cytoplasmic domain)

  • Compare full-length PLSCR4 (membrane-localized) with truncated forms (1-290, diffuse nucleo-cytoplasmic)

  • Perform competitive binding studies with SLPI to disrupt PLSCR4-CD4 interactions

• Functional consequences:

  • Assess HIV-1 infection efficiency in cells with modified PLSCR4-CD4 interaction

  • Monitor CD4 signaling in T cells with altered PLSCR4 expression

  • Investigate changes in CD4 trafficking and membrane microdomain localization

• Controls and validations:

  • Include PLSCR1 as a comparative control (also interacts with CD4)

  • Use CD4-negative cells as specificity controls

  • Implement SLPI treatment to disrupt interactions as a functional validation

Research indicates that both PLSCR1 and PLSCR4 interact directly with the CD4 receptor at the cell surface of T lymphocytes. The same region of the cytoplasmic domain of PLSCR1 is involved in binding to CD4 and the secretory leukocyte protease inhibitor (SLPI). This interaction may be important for modulating HIV-1 infection, as SLPI can disrupt the association between PLSCR1 and CD4 .

What are the recommended protocols for PLSCR4 knockdown validation in functional studies?

For robust PLSCR4 knockdown validation, implement this comprehensive protocol:

• siRNA design and validation:

  • Target at least 3 different regions of PLSCR4 mRNA

  • Design siRNAs with 30-50% GC content and minimal off-target effects

  • Include scrambled siRNA controls with similar GC content

  • Validate knockdown efficiency at both mRNA (qRT-PCR) and protein (western blot) levels

• Transfection optimization:

  • For HPMECs: Use Lipofectamine 2000 at 1:3 ratio (siRNA:lipofectamine)

  • For primary T cells: Consider nucleofection or specialized transfection reagents

  • Optimize cell density (60-70% confluence recommended)

  • Determine optimal siRNA concentration (typically 20-40 nM)

• Functional validation methods:

  • Measure PS translocation using Annexin V binding assays

  • Assess barrier integrity through tracer flux assays

  • Quantify inflammatory cytokine release (IL-1β, IL-18)

  • Evaluate cell viability and pyroptosis markers

• Time-course considerations:

  • Assess knockdown kinetics (typically maximal at 48-72h post-transfection)

  • Design experiments within the window of maximal knockdown

  • Consider potential compensatory mechanisms by other PLSCR family members

When conducting in vivo knockdown experiments, the established protocol for mouse models involves injecting a complex of PLSCR4 siRNA/scramble siRNA with Lipofectamine 2000 through the fundus venous plexus. The recommended dosage is 150 μL of PLSCR4 siRNA (40 μM) combined with 16 μL Lipofectamine 2000 diluted in 100 μL DEPC-treated water .

How can researchers identify and validate transcription factors regulating PLSCR4 expression?

To identify and validate transcription factors regulating PLSCR4 expression, follow this methodological approach:

• Bioinformatic prediction:

  • Analyze the PLSCR4 promoter sequence using JASPAR, TRANSFAC, or similar databases

  • Identify conserved transcription factor binding sites across species

  • Prioritize factors relevant to cellular contexts of interest (e.g., inflammatory conditions)

• DNA pull-down assays:

  • Synthesize biotinylated PLSCR4 promoter sequence probes

  • Couple biotin probes with streptavidin-coated magnetic beads

  • Extract nuclear proteins from cells of interest (control vs. experimental conditions)

  • Perform pull-down followed by western blot or mass spectrometry

• Chromatin immunoprecipitation (ChIP):

  • Perform ChIP with antibodies against predicted transcription factors

  • Design primers flanking putative binding sites in the PLSCR4 promoter

  • Quantify enrichment by qPCR or sequencing (ChIP-seq)

  • Compare binding under different physiological conditions

• Functional validation:

  • Perform site-directed mutagenesis of binding sites in reporter constructs

  • Assess transcription factor overexpression/knockdown effects on PLSCR4 expression

  • Use CRISPR-Cas9 to modify endogenous binding sites

Research using DNA pull-down and protein profiling techniques has identified P62280 as a potential transcription factor for PLSCR4. The analysis involved LC-MS/MS technology to analyze protein fragments' charge and peak maps, revealing significant enrichment of P62280 in the experimental group compared to controls .

What methods are most effective for studying PLSCR4's role in phospholipid translocation?

For investigating PLSCR4's phospholipid translocation activity, implement these methodological approaches:

• Fluorescent lipid translocation assays:

  • Use NBD-labeled phospholipids to track movement across membranes

  • Implement FACS-based protocols to quantify PS externalization

  • Apply dithionite to quench externally accessible NBD-lipids

  • Compare Ca²⁺-dependent versus independent scrambling activity

• Annexin V binding assays:

  • Use fluorescently-labeled Annexin V to detect PS externalization

  • Implement live-cell imaging to track PS dynamics in real-time

  • Correlate PS exposure with other cellular events (e.g., pyroptosis)

  • Compare wild-type versus PLSCR4-deficient cells

• Liposome reconstitution systems:

  • Purify recombinant PLSCR4 for incorporation into artificial membranes

  • Measure lipid scrambling in controlled membrane environments

  • Test effects of calcium concentration on activation kinetics

  • Analyze scrambling selectivity for different phospholipid species

• Correlation with functional outcomes:

  • Link PS externalization to pyroptosis inhibition

  • Measure membrane permeability changes (e.g., YO-PRO uptake)

  • Assess inflammatory cytokine release (IL-1β, IL-18)

  • Correlate with barrier integrity in endothelial models

Research has shown that PLSCR4 alleviates pyroptosis by transporting PS to the outside of the cell membrane, which blocks the formation of pyroptosis pores composed of GSDMD. When PLSCR4 expression is elevated, the distribution of PS and N-terminal cleavage product (GSDMD-NT) of GSDMD increases on the external side of the cell membrane, correlating with reduced cellular injury and inflammatory cytokine release .

How should researchers interpret conflicting data between PLSCR4 expression and functional outcomes?

When facing discrepancies between PLSCR4 expression and observed functional outcomes, consider this systematic interpretation framework:

• Context-dependent activity assessment:

  • Evaluate calcium levels across experimental conditions (PLSCR4 is Ca²⁺-dependent)

  • Assess post-translational modifications affecting PLSCR4 function

  • Consider cell type-specific factors influencing PLSCR4 activity

  • Analyze membrane composition differences affecting scramblase function

• Compensatory mechanism evaluation:

  • Measure expression of other PLSCR family members (PLSCR1, PLSCR3)

  • Assess alternative phospholipid translocation pathways (e.g., ANO6/TMEM16F)

  • Investigate downstream effector availability (e.g., GSDMD levels)

  • Consider pathway redundancies that might mask PLSCR4-specific effects

• Experimental timing considerations:

  • Implement time-course experiments to capture transient effects

  • Distinguish between acute and adaptive responses

  • Consider the kinetics of PLSCR4 activation relative to functional readouts

  • Account for feedback loops that may restore homeostasis

• Integrative data analysis:

  • Correlate PLSCR4 activity (not just expression) with functional outcomes

  • Implement multivariate analysis to identify confounding variables

  • Use principal component analysis to determine major contributors to variance

  • Develop predictive models incorporating multiple parameters

Research shows that while PLSCR4 expression correlates with decreased IL-1β and IL-18 release and reduced barrier damage in ARDS models, the pyroptosis-relevant proteins GSDMD and caspase-1 are not significantly altered. This suggests that PLSCR4's protective effect operates through modulating protein localization and activity rather than expression levels .

What are the common pitfalls in PLSCR4 antibody-based research and how can they be overcome?

Researchers should be aware of these common pitfalls and their solutions when working with PLSCR4 antibodies:

• Antibody specificity issues:

  • Pitfall: Cross-reactivity with other PLSCR family members

  • Solution: Validate using PLSCR4 knockout/knockdown samples and recombinant protein controls

  • Approach: Include multiple antibodies targeting different epitopes to confirm findings

• Conformational epitope masking:

  • Pitfall: Calcium-binding or protein interactions may mask epitopes

  • Solution: Compare native versus denatured detection methods

  • Approach: Use multiple antibodies targeting different regions (N-terminal, central, C-terminal)

• Subcellular localization artifacts:

  • Pitfall: Fixation can alter membrane protein distribution

  • Solution: Compare multiple fixation methods (PFA, methanol, acetone)

  • Approach: Complement with live-cell imaging of tagged PLSCR4

• Quantification challenges:

  • Pitfall: Variable expression across cell types and conditions

  • Solution: Use stable internal controls and relative quantification

  • Approach: Implement absolute quantification using recombinant protein standards

• Functional correlation issues:

  • Pitfall: Detecting PLSCR4 presence doesn't confirm activity

  • Solution: Pair expression studies with functional assays

  • Approach: Correlate antibody staining with PS externalization measurements

Research by Py et al. demonstrated that using truncated forms of PLSCR4 (such as 1-290) that lack the transmembrane domain results in diffuse nucleo-cytoplasmic distribution rather than plasma membrane localization. This illustrates how protein modifications can dramatically alter localization patterns and potentially lead to misinterpretation of antibody-based detection results .

How can PLSCR4 antibodies be utilized to investigate its role in viral infection beyond HIV?

To explore PLSCR4's role in broader viral infections, consider these methodological approaches:

• Comparative viral entry studies:

  • Use PLSCR4 antibodies to block or detect protein during viral challenge

  • Compare multiple virus families (enveloped vs. non-enveloped)

  • Assess virus-induced changes in PLSCR4 expression and localization

  • Correlate PS externalization with viral fusion efficiency

• Co-receptor interaction analysis:

  • Investigate PLSCR4 interactions with known viral receptors

  • Perform co-immunoprecipitation followed by western blotting

  • Use proximity ligation assays to visualize interactions in situ

  • Assess competitive binding between viral proteins and PLSCR4's normal binding partners

• Virus-induced membrane remodeling:

  • Track PLSCR4 redistribution during viral replication

  • Correlate with viral replication complex formation

  • Investigate PLSCR4's role in viral budding processes

  • Assess PS redistribution in virus-containing compartments

• Innate immune signaling:

  • Explore PLSCR4's potential role in pathogen recognition

  • Investigate interactions with pattern recognition receptors

  • Assess impact on type I interferon production

  • Evaluate inflammatory cytokine responses in PLSCR4-modulated cells

Current research has identified that PLSCR1 and PLSCR4 interact directly with the CD4 receptor on T lymphocytes and that the secretory leukocyte protease inhibitor (SLPI) can disrupt this association, inhibiting HIV-1 infection. This suggests a model where scramblases may play important roles in viral receptor function that could extend beyond HIV to other viral pathogens .

What are the emerging techniques for studying PLSCR4 in relation to cell death pathways beyond pyroptosis?

To investigate PLSCR4's role in diverse cell death pathways, implement these cutting-edge approaches:

• Multi-parameter cell death profiling:

  • Use flow cytometry panels detecting multiple death markers simultaneously

  • Combine Annexin V (PS externalization) with cell death-specific markers

  • Implement live-cell imaging with multiplexed death pathway reporters

  • Correlate PLSCR4 activity with various death signatures in real-time

• Phospholipidomic analysis:

  • Apply lipidomic mass spectrometry to track membrane composition changes

  • Quantify specific phospholipid species across cellular compartments

  • Compare lipid redistribution patterns in different death pathways

  • Correlate with PLSCR4 activation states

• CRISPR-based functional screening:

  • Perform CRISPR screens targeting cell death regulators in PLSCR4-modified cells

  • Identify synthetic lethal interactions with PLSCR4

  • Discover novel pathway connections through genetic perturbation

  • Validate hits with targeted knockdown/knockout approaches

• Spatial proteomics:

  • Implement proximity labeling techniques (BioID, APEX) with PLSCR4 as bait

  • Map PLSCR4's interactome across different death-inducing conditions

  • Use subcellular fractionation coupled with proteomics

  • Track dynamic changes in protein interactions during death progression

Research has established PLSCR4's role in pyroptosis through its interaction with GSDMD and PS externalization, suggesting it may function as a regulatory mechanism in programmed cell death. This foundation provides a starting point for exploring its potential involvement in other death pathways such as apoptosis, necroptosis, or ferroptosis, particularly through its fundamental role in phospholipid scrambling .